Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) - PubMed
3 days ago
- #immunotherapy
- #breast cancer
- #clinical trial
- Phase II trial (SOLTI-1503 PROMETEO) investigated T-VEC (oncolytic virus) + atezolizumab (anti-PD-L1) in HER2-negative breast cancer post-neoadjuvant chemotherapy.
- 28 patients enrolled: 20 HR+/HER2-negative, 8 TNBC. 26.9% achieved RCB-0/I (primary endpoint).
- Safety profile was favorable with low-grade adverse events and no serious events (secondary endpoint).
- Therapy induced immune modulation: increased tumor-infiltrating lymphocytes, elevated PD-L1 expression, enhanced immune-related gene signatures (exploratory endpoints).
- Findings support feasibility of T-VEC + atezolizumab as preoperative immunotherapy for HER2-negative residual disease, warranting further trials.